Search

Your search keyword '"Kuhl, C."' showing total 663 results
Start Over Author "Kuhl, C."
663 results on '"Kuhl, C."'

3. An investigation of pedigree dog breeding and ownership in the UK : experiences and opinions of veterinary surgeons, pedigree dog breeders and dog owners

Author

Kuhl, C.

Subjects
636.7, SF Animal culture
Abstract

Pedigree dog welfare in the United Kingdom is a controversial subject. This PhD aimed to investigate small animal veterinary surgeons’ (VS), pedigree dog breeders’ (PDB) and owners’ perceptions surrounding canine health, their roles, information acquisition and the quality of online resources available to new dog owners. Via a mixed-methods approach VS and PDB were asked about their perceptions of pedigree dog welfare using online questionnaires. Focus groups were then used to explore these parties’ opinions on advising dog owners and buyers. Dog owners were administered an online questionnaire to explore drivers of dog acquisition and sourcing of information about canine health. A further sample of dog owners provided possible internet search terms they would use to find information on how to care for a new dog. These terms were used for a scoping review to examine the quality of available information. The VS and PDB exhibited varied perceptions relating to pedigree dog breeding, inherited disease and health screening programmes. Each group considered themselves the most knowledgeable on these topics and lacked clarity on how their roles interrelated. Focus groups showed conflicting views on advising dog owners and buyers. Dog owners varied in their drivers for ownership, from whom they obtained information and the internet search terms used when looking for information online. The scoping review identified a lot of easy to understand, poor quality information. VS and PDB need to better understand and appreciate each others’ roles, perspectives and knowledge to instigate effective collaboration and improve pedigree dog health. Owners are diverse and require a multifaceted educational approach to improve knowledge. The quality of online information for owners needs to be made clear and a coordinated approach involving all stakeholders is required to enable dissemination of practical, evidence-based information on pedigree dog health.

Published
2017

11. Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline

Author

Sessa, C., Balmaña, J., Bober, S. L., Cardoso, Maria-Joao, Colombo, N., Curigliano, G., Domchek, S. M., Evans, D. G., Fischerova, D., Harbeck, N., Kuhl, C., Lemley, B., Levy-Lahad, E., Lambertini, M., Ledermann, J. A., Loibl, S., Phillips, K.-A., Paluch-Shimon, S., Repositório da Universidade de Lisboa, Sessa, C, Balmana, J, Bober, S, Cardoso, M, Colombo, N, Curigliano, G, Domchek, S, Evans, D, Fischerova, D, Harbeck, N, Kuhl, C, Lemley, B, Levy-Lahad, E, Lambertini, M, Ledermann, J, Loibl, S, Phillips, K, and Paluch-Shimon, S

Subjects
hereditary breast and ovarian cancer syndrome, Oncology, ESMO Clinical Practice Guideline, Hereditary breast and ovarian cancer syndromes, BRCA, Risk reduction, Hematology
Abstract

© 2022 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved

Published
2023

37. Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline

Author

Sessa, C., primary, Balmaña, J., additional, Bober, S.L., additional, Cardoso, M.J., additional, Colombo, N., additional, Curigliano, G., additional, Domchek, S.M., additional, Evans, D.G., additional, Fischerova, D., additional, Harbeck, N., additional, Kuhl, C., additional, Lemley, B., additional, Levy-Lahad, E., additional, Lambertini, M., additional, Ledermann, J.A., additional, Loibl, S., additional, Phillips, K.-A., additional, and Paluch-Shimon, S., additional

Published
2023
Full Text
View/download PDF

38. MEDLI2 Flight Heat Flux Sensor Environment and Planetary Protection Testing

Author

Swanson, G. T, Miller, R. A, Oishi, T, Santos, J. A, Rutherford, G. N, Liles, K. A, Kuhl, C. A, Schreck, D. E, White, T. R, and Wright, H. S

Subjects
Instrumentation And Photography, Spacecraft Design, Testing And Performance
Abstract

Mars 2020 will fly the Mars Entry, Descent, and Landing Instrumentation II (MEDLI2) sensor suite consisting of a total of seventeen instrumented thermocouple sensor plugs, eight pressure transducers, two total heat flux sensors, and one radiometer embedded in the thermal protection system (TPS). Of the MEDLI2 instrumentation, eleven instrumented thermocouple plugs and seven pressure transducers will be installed on the heatshield of the Mars 2020 vehicle while the rest will be installed on the backshell. The goal of the MEDLI2 instrumentation is to directly inform the large performance uncertainties that contribute to the design and validation of a Mars entry system. A better understanding of the entry environment and TPS performance could lead to reduced design margins enabling greater payload mass-fraction and smaller landing ellipses. The MEDLI2 total heat flux sensors and radiometer are new instruments that were not flown on the Mars Science Laboratory mission. These sensors directly measure the surface heat flux and radiation at specific backshell locations. The total heat flux sensors use a Schmidt-Boelter sensing element. The radiometer version uses a sapphire window placed over the Schmidt-Boelter sensing element to separate the radiative component of the total heat flux. MEDLI2 recently planned and executed protoflight environmental testing as well planetary protection measures on the flight and flight-spare total heat flux sensors and radiometers. This testing is required to provide confidence in the performance of the flight-lot sensors when exposed to flight-like environments, and to reduce the risk of biological contamination on the planet of Mars with microbes from Earth.

Published
2019

41. Clinical Application of Trans-Arterial Radioembolization in Hepatic Malignancies in Europe: First Results from the Prospective Multicentre Observational Study CIRSE Registry for SIR-Spheres Therapy (CIRT)

Author

Helmberger T., Golfieri R., Pech M., Pfammatter T., Arnold D., Cianni R., Maleux G., Munneke G., Pellerin O., Peynircioglu B., Sangro B., Schaefer N., de Jong N., Bilbao J. I., Pelage J. -P., Manas D. M., Kolligs F. T., Ezziddin S., Peters R., Albrecht T., D'Archambeau O., Balli T., Bilgic S., Bloom A., Cioni R., Fischbach R., Flamen P., Gerard L., Grozinger G., Katoh M., Koehler M., Kroger J. R., Kuhl C., Orsi F., Ozgun M., Reimer P., Ronot M., Schmid A., Vit A., Helmberger T., Golfieri R., Pech M., Pfammatter T., Arnold D., Cianni R., Maleux G., Munneke G., Pellerin O., Peynircioglu B., Sangro B., Schaefer N., de Jong N., Bilbao J.I., Pelage J.-P., Manas D.M., Kolligs F.T., Ezziddin S., Peters R., Albrecht T., D'Archambeau O., Balli T., Bilgic S., Bloom A., Cioni R., Fischbach R., Flamen P., Gerard L., Grozinger G., Katoh M., Koehler M., Kroger J.R., Kuhl C., Orsi F., Ozgun M., Reimer P., Ronot M., Schmid A., Vit A., University of Zurich, On behalf of the CIRT Steering Committee, On behalf of the CIRT Principal Investigators, Pelage, J.P., Manas, D.M., Kolligs, F.T., Ezziddin, S., Peters, R., Albrecht, T., D'Archambeau, O., Balli, T., Bilgic, S., Bloom, A., Cioni, R., Fischbach, R., Flamen, P., Gerard, L., Grözinger, G., Katoh, M., Koehler, M., Kröger, J.R., Kuhl, C., Orsi, F., Ozgun, M., Reimer, P., Ronot, M., Schmid, A., and Vit, A.

Subjects
Male, Registrie, SIR-Spheres, Yttrium-90, Cardiac & Cardiovascular Systems, Tare weight, Colorectal cancer, Hepatocellular carcinoma, medicine.medical_treatment, Metastasi, Radioisotope brachytherapy, COLORECTAL-CANCER, Metastasis, 030218 nuclear medicine & medical imaging, 0302 clinical medicine, Observational study, Medicine, Yttrium Radioisotopes, Prospective Studies, Registries, SALVAGE THERAPY, Y-90 RADIOEMBOLIZATION, 10042 Clinic for Diagnostic and Interventional Radiology, Incidence, Mortality rate, Radiology, Nuclear Medicine & Medical Imaging, Liver Neoplasms, CANCER LIVER METASTASES, Middle Aged, Embolization, Therapeutic, Microspheres, Europe, Trans-arterial radioembolization, Liver, SAFETY, 030220 oncology & carcinogenesis, Female, Cardiology and Cardiovascular Medicine, Life Sciences & Biomedicine, medicine.medical_specialty, Carcinoma, Hepatocellular, 610 Medicine & health, Context (language use), Therapeutic embolization, 03 medical and health sciences, Breast cancer, GLASS MICROSPHERES, ADVANCED HEPATOCELLULAR-CARCINOMA, Pancreatic cancer, Internal medicine, INTRAHEPATIC CHOLANGIOCARCINOMA, Humans, Radiology, Nuclear Medicine and imaging, Clinical Investigation, Retrospective Studies, Science & Technology, INTERNAL RADIATION-THERAPY, business.industry, EFFICACY, medicine.disease, Radiography, Cardiovascular System & Cardiology, business
Abstract

Purpose To address the lack of prospective data on the real-life clinical application of trans-arterial radioembolization (TARE) in Europe, the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) initiated the prospective observational study CIRSE Registry for SIR-Spheres® Therapy (CIRT). Materials and Methods Patients were enrolled from 1 January 2015 till 31 December 2017. Eligible patients were adult patients treated with TARE with Y90 resin microspheres for primary or metastatic liver tumours. Patients were followed up for 24 months after treatment, whereas data on the clinical context of TARE, overall survival (OS) and safety were collected. Results Totally, 1027 patients were analysed. 68.2% of the intention of treatment was palliative. Up to half of the patients received systemic therapy and/or locoregional treatments prior to TARE (53.1%; 38.3%). Median overall survival (OS) was reported per cohort and was 16.5 months (95% confidence interval (CI) 14.2–19.3) for hepatocellular carcinoma, 14.6 months (95% CI 10.9–17.9) for intrahepatic cholangiocarcinoma. For liver metastases, median OS for colorectal cancer was 9.8 months (95% CI 8.3–12.9), 5.6 months for pancreatic cancer (95% CI 4.1–6.6), 10.6 months (95% CI 7.3–14.4) for breast cancer, 14.6 months (95% CI 7.3–21.4) for melanoma and 33.1 months (95% CI 22.1–nr) for neuroendocrine tumours. Statistically significant prognostic factors in terms of OS include the presence of ascites, cirrhosis, extra-hepatic disease, patient performance status (Eastern Cooperative Oncology Group), number of chemotherapy lines prior to TARE and tumour burden. Thirty-day mortality rate was 1.0%. 2.5% experienced adverse events grade 3 or 4 within 30 days after TARE. Conclusion In the real-life clinical setting, TARE is largely considered to be a part of a palliative treatment strategy across indications and provides an excellent safety profile. Level of evidence Level 3. Trial registration ClinicalTrials.gov NCT02305459.

Published
2021

45. Mamma

Author

Kuhl, C., Reimer, Peter, editor, Parizel, Paul M., editor, and Stichnoth, Falko-A., editor

Published
2003
Full Text
View/download PDF

46. Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib

Author

Öcal, Osman, Schinner, Regina, Schütte, Kerstin, de Toni, Enrico N., Loewe, Christian, van Delden, Otto, Vandecaveye, Vincent, Gebauer, Bernhard, Zech, Christoph J., Sengel, Christian, Bargellini, Irene, Gasbarrini, Antonio, Sangro, Bruno, Pech, Maciej, Malfertheiner, Peter, Ricke, Jens, Seidensticker, Max, Kettner, E., Amthauer, H., Cwikla, J., Walecki, J., Klümpen, H., Schott, E., Kolligs, F., Rosmorduc, O., Menu, Y., Leroy, V., Mayerle, J., Trumm, C., Bartenstein, P., Reiser, M., Berg, T., Moche, M., Bilbao, I., Gossner, L., Reimer, P., Popovic, P., Stabuc, B., Piasecki, P., Podgajny, Z., Sacco, R., Peck-Radosavljevic, M., Lammer, J., Maleux, G., Verslype, C., Rosenberg, C., Nitsche, D., Waldenberger, P., Vergniol, J., Cassinotto, C., Yalcin, S., Peynircioglu, B., Zavaglia, C., Rampoldi, A., Tran, A., Chevallier, P., Anty, R., Trautwein, C., Kuhl, C., Grazioli, L., Vogl, T., Trojan, J., Bartolozzi, C., Iezzi, R., Bronowicki, J. P., Palmer, D., Evans, J., Sharma, R., Weir, G., Hubner, R., Basu, B., Ross, P., Internal medicine, Apollo - University of Cambridge Repository, Kettner, E., Amthauer, H., Cwikla, J., Walecki, J., Klümpen, H., Schott, E., Kolligs, F., Rosmorduc, O., Menu, Y., Leroy, V., Mayerle, J., Trumm, C., Bartenstein, P., Reiser, M., Berg, T., Moche, M., Bilbao, I., Gossner, L., Reimer, P., Popovic, P., Stabuc, B., Piasecki, P., Podgajny, Z., Sacco, R., Peck-Radosavljevic, M., Lammer, J., Maleux, G., Verslype, C., Rosenberg, C., Nitsche, D., Waldenberger, P., Vergniol, J., Cassinotto, C., Yalcin, S., Peynircioglu, B., Zavaglia, C., Rampoldi, A., Tran, A., Chevallier, P., Anty, R., Trautwein, Christian, Kuhl, Christiane, Grazioli, L., Vogl, T., Trojan, J., Bartolozzi, C., Iezzi, R., Bronowicki, J. P., Palmer, D., Evans, J., Sharma, R., Weir, G., Hubner, R., Basu, B., Ross, P., Radiology and Nuclear Medicine, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, CCA -Cancer Center Amsterdam, Oncology, and CCA - Cancer Treatment and Quality of Life

Subjects
Male, Carcinoma, Hepatocellular, Radiological and Ultrasound Technology, Hepatocellular carcinoma, Settore MED/09 - MEDICINA INTERNA, Liver Neoplasms, R895-920, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Antineoplastic Agents, General Medicine, Sorafenib, mRECIST, Medical physics. Medical radiology. Nuclear medicine, Early tumor shrinkage, Treatment Outcome, Oncology, Objective response, Humans, Radiology, Nuclear Medicine and imaging, RC254-282, Research Article, Retrospective Studies
Abstract

Cancer imaging 22, 1 (2022). doi:10.1186/s40644-021-00439-x, Published by BioMed Central, London

Published
2022
Full Text
View/download PDF

47. Ein retrospektiver Vergleich der gezielten MRT/TRUS Fusionsbiopsie mit systematischer Biopsie mit der Detektionsrate von Prostatakarzinomen in der mpMRT

Author

Pham, T, Schulze-Hagen, M, Kuhl, C, Saar, M, and Rahnama'i, S

Subjects
ddc: 610, Medicine and health
Abstract

Einleitung: Patienten mit Verdacht auf ein Prostatakarzinom unterziehen sich in der Regel einer transrektalen ultraschallgesteuerten (TRUS) systematischen Biopsie, welche potentiell sowohl relevante Prostatakarzinome verfehlen als auch zu einer ��bertherapie f��hren kann. Die multiparametrische [zum vollst��ndigen Text gelangen Sie ��ber die oben angegebene URL]

Published
2022
Full Text
View/download PDF

48. MR-Mammographie

Author

Kuhl, C., Reimer, Peter, editor, Parizel, Paul M., editor, and Stichnoth, Falko-A., editor

Published
2000
Full Text
View/download PDF

50. MELDI2 Do No Harm Test Series

Author

Swanson, G. T, Santos, J. A, White, T. R, Bruce, W. E, Kuhl, C. A, and Wright, H. S

Subjects
Spacecraft Instrumentation And Astrionics, Spacecraft Design, Testing And Performance
Abstract

Mars 2020 will fly the Mars Entry, Descent, and Landing Instrumentation II (MEDLI2) sensor suite consisting of a total of seventeen instrumented thermal sensor plugs, eight pressure transducers, two heat flux sensors, and one radiometer embedded in the thermal protection system (TPS). Of the MEDLI2 instrumentation, eleven instrumented thermal plugs and seven pressure transducers will be installed on the heatshield of the Mars 2020 vehicle while the rest will be installed on the backshell. The goal of the MEDLI2 instrumentation is to directly inform the large performance uncertainties that contribute to the design and validation of a Mars entry system. A better understanding of the entry environment and TPS performance could lead to reduced design margins enabling a greater payload mass-fraction and smaller landing ellipses. To prove that the MEDLI2 system will not degrade the performance of the Mars 2020 TPS, an Aerothermal Do No Harm (DNH) test series was designed and conducted. Like Mars 2020's predecessor, Mars Science Laboratory (MSL), the heatshield material will be Phenolic Impregnated Carbon Ablator (PICA); the Mars 2020 entry conditions are enveloped by the MSL design environments, therefore the development and qualification testing performed during MEDLI is sufficient to show that the similar MEDLI2 heatshield instrumentation will not degrade PICA performance. However, given that MEDLI did not include any backshell instrumentation, the MEDLI2 team was required to design and execute a DNH test series utilizing the backshell TPS material (SLA-561V) with the intended flight sensor suite. To meet the requirements handed down from Mars 2020, the MEDLI2 DNH test series emphasized the interaction between the MEDLI2 sensors and sensing locations with the surrounding backshell TPS and substrucutre. These interactions were characterized by performing environmental testing of four 12" by 12" test panels, which mimicked the construction of the backshell TPS and the integration of the MEDLI2 sensors as seen in Figure 1. The testing included thermal vacuum/ cycling, random vibration, shock, and arc jet testing. The test panels were fabricated by Lockheed Martin, establishing techniques that will be utilized during the Mars 2020 vehicle installation. Each test panel included one thermal sensor plug (two embedded thermocouples), one heat flux sensor, and multiple pressure port holes for evaluation. This presentation will discuss the planning and execution of the MEDLI2 DNH test series. Selected highlights and results of each environmental test will be presented, and lessons learned will be addressed that will feed forward into the planning for the MEDLI2 flight system certification testing.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results